ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
Clin Microbiol Infect 2012; 18 (Suppl. 7): 68–77 Mucosal candidiasis is frequent in immunocompromised HIV‐infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2012-12, Vol.18, p.68-77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | |
| container_start_page | 68 |
| container_title | Clinical microbiology and infection |
| container_volume | 18 |
| creator | Lortholary, O. Petrikkos, G. Akova, M. Arendrup, M. C. Arikan‐Akdagli, S. Bassetti, M. Bille, J. Calandra, T. Castagnola, E. Cornely, O. A. Cuenca‐Estrella, M. Donnelly, J. P. Garbino, J. Groll, A. H. Herbrecht, R. Hope, W. W. Jensen, H. E. Kullberg, B. J. Lass‐Flörl, C. Meersseman, W. Richardson, M. D. Roilides, E. Verweij, P. E. Viscoli, C. Ullmann, A. J. |
| description | Clin Microbiol Infect 2012; 18 (Suppl. 7): 68–77
Mucosal candidiasis is frequent in immunocompromised HIV‐infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre‐HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole‐refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred. |
| doi_str_mv | 10.1111/1469-0691.12042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273136347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273136347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3842-b4ea42a0d6a0198eb440457e301eb1ddb0fb8102feeeff01bdf2e0242c0b7a603</originalsourceid><addsrcrecordid>eNqFkLtOwzAUQC0E4lGY2ZBHltDrR5OUDaUFIrVi4CE2y4mvi1EeJU5V8fe4tHTFi62r4yPdQ8glgxsWzpDJeBxBPGY3jIPkB-R0PzkMbzZOo0SK9xNy5v0nAHAh5DE54YKJhIn0lLTT52yeT-hi5QxWrkFq2472H0iN04um9c5T3Rha60YvsMamp62lWRg5owPjUXv0lAPjt3SpexcIT9eu_6CP-Rt1jcWyd21Dg_UunzyfkyOrK48Xu3tAXu-nL9ljNHt6yLO7WVSKVPKokKgl12BiDWEJLKQEOUpQAMOCGVOALVIG3CKitcAKYzkCl7yEItExiAG53nqXXfu1Qt-r2vkSq0o32K68YjwJDWIhk4AOt2jZtd53aNWyc7XuvhUDtamsNk3Vpqn6rRx-XO3kq6JGs-f_sgZgtAXWrsLv_3wqm8234h-uQoVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273136347</pqid></control><display><type>article</type><title>ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lortholary, O. ; Petrikkos, G. ; Akova, M. ; Arendrup, M. C. ; Arikan‐Akdagli, S. ; Bassetti, M. ; Bille, J. ; Calandra, T. ; Castagnola, E. ; Cornely, O. A. ; Cuenca‐Estrella, M. ; Donnelly, J. P. ; Garbino, J. ; Groll, A. H. ; Herbrecht, R. ; Hope, W. W. ; Jensen, H. E. ; Kullberg, B. J. ; Lass‐Flörl, C. ; Meersseman, W. ; Richardson, M. D. ; Roilides, E. ; Verweij, P. E. ; Viscoli, C. ; Ullmann, A. J.</creator><creatorcontrib>Lortholary, O. ; Petrikkos, G. ; Akova, M. ; Arendrup, M. C. ; Arikan‐Akdagli, S. ; Bassetti, M. ; Bille, J. ; Calandra, T. ; Castagnola, E. ; Cornely, O. A. ; Cuenca‐Estrella, M. ; Donnelly, J. P. ; Garbino, J. ; Groll, A. H. ; Herbrecht, R. ; Hope, W. W. ; Jensen, H. E. ; Kullberg, B. J. ; Lass‐Flörl, C. ; Meersseman, W. ; Richardson, M. D. ; Roilides, E. ; Verweij, P. E. ; Viscoli, C. ; Ullmann, A. J. ; ESCMID Fungal Infection Study Group</creatorcontrib><description>Clin Microbiol Infect 2012; 18 (Suppl. 7): 68–77
Mucosal candidiasis is frequent in immunocompromised HIV‐infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre‐HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole‐refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1111/1469-0691.12042</identifier><identifier>PMID: 23137138</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antifungal Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Candida - drug effects ; Candida - isolation & purification ; Candidiasis ; Candidiasis - complications ; Candidiasis - diagnosis ; Candidiasis - drug therapy ; Candidiasis - prevention & control ; Europe ; Evidence-Based Medicine - standards ; guideline ; HIV AIDS ; HIV Infections - complications ; Humans ; Immunocompromised Host</subject><ispartof>Clinical microbiology and infection, 2012-12, Vol.18, p.68-77</ispartof><rights>2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3842-b4ea42a0d6a0198eb440457e301eb1ddb0fb8102feeeff01bdf2e0242c0b7a603</citedby><cites>FETCH-LOGICAL-c3842-b4ea42a0d6a0198eb440457e301eb1ddb0fb8102feeeff01bdf2e0242c0b7a603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1469-0691.12042$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1469-0691.12042$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23137138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lortholary, O.</creatorcontrib><creatorcontrib>Petrikkos, G.</creatorcontrib><creatorcontrib>Akova, M.</creatorcontrib><creatorcontrib>Arendrup, M. C.</creatorcontrib><creatorcontrib>Arikan‐Akdagli, S.</creatorcontrib><creatorcontrib>Bassetti, M.</creatorcontrib><creatorcontrib>Bille, J.</creatorcontrib><creatorcontrib>Calandra, T.</creatorcontrib><creatorcontrib>Castagnola, E.</creatorcontrib><creatorcontrib>Cornely, O. A.</creatorcontrib><creatorcontrib>Cuenca‐Estrella, M.</creatorcontrib><creatorcontrib>Donnelly, J. P.</creatorcontrib><creatorcontrib>Garbino, J.</creatorcontrib><creatorcontrib>Groll, A. H.</creatorcontrib><creatorcontrib>Herbrecht, R.</creatorcontrib><creatorcontrib>Hope, W. W.</creatorcontrib><creatorcontrib>Jensen, H. E.</creatorcontrib><creatorcontrib>Kullberg, B. J.</creatorcontrib><creatorcontrib>Lass‐Flörl, C.</creatorcontrib><creatorcontrib>Meersseman, W.</creatorcontrib><creatorcontrib>Richardson, M. D.</creatorcontrib><creatorcontrib>Roilides, E.</creatorcontrib><creatorcontrib>Verweij, P. E.</creatorcontrib><creatorcontrib>Viscoli, C.</creatorcontrib><creatorcontrib>Ullmann, A. J.</creatorcontrib><creatorcontrib>ESCMID Fungal Infection Study Group</creatorcontrib><title>ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Clin Microbiol Infect 2012; 18 (Suppl. 7): 68–77
Mucosal candidiasis is frequent in immunocompromised HIV‐infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre‐HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole‐refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.</description><subject>Antifungal Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Candida - drug effects</subject><subject>Candida - isolation & purification</subject><subject>Candidiasis</subject><subject>Candidiasis - complications</subject><subject>Candidiasis - diagnosis</subject><subject>Candidiasis - drug therapy</subject><subject>Candidiasis - prevention & control</subject><subject>Europe</subject><subject>Evidence-Based Medicine - standards</subject><subject>guideline</subject><subject>HIV AIDS</subject><subject>HIV Infections - complications</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUQC0E4lGY2ZBHltDrR5OUDaUFIrVi4CE2y4mvi1EeJU5V8fe4tHTFi62r4yPdQ8glgxsWzpDJeBxBPGY3jIPkB-R0PzkMbzZOo0SK9xNy5v0nAHAh5DE54YKJhIn0lLTT52yeT-hi5QxWrkFq2472H0iN04um9c5T3Rha60YvsMamp62lWRg5owPjUXv0lAPjt3SpexcIT9eu_6CP-Rt1jcWyd21Dg_UunzyfkyOrK48Xu3tAXu-nL9ljNHt6yLO7WVSKVPKokKgl12BiDWEJLKQEOUpQAMOCGVOALVIG3CKitcAKYzkCl7yEItExiAG53nqXXfu1Qt-r2vkSq0o32K68YjwJDWIhk4AOt2jZtd53aNWyc7XuvhUDtamsNk3Vpqn6rRx-XO3kq6JGs-f_sgZgtAXWrsLv_3wqm8234h-uQoVs</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Lortholary, O.</creator><creator>Petrikkos, G.</creator><creator>Akova, M.</creator><creator>Arendrup, M. C.</creator><creator>Arikan‐Akdagli, S.</creator><creator>Bassetti, M.</creator><creator>Bille, J.</creator><creator>Calandra, T.</creator><creator>Castagnola, E.</creator><creator>Cornely, O. A.</creator><creator>Cuenca‐Estrella, M.</creator><creator>Donnelly, J. P.</creator><creator>Garbino, J.</creator><creator>Groll, A. H.</creator><creator>Herbrecht, R.</creator><creator>Hope, W. W.</creator><creator>Jensen, H. E.</creator><creator>Kullberg, B. J.</creator><creator>Lass‐Flörl, C.</creator><creator>Meersseman, W.</creator><creator>Richardson, M. D.</creator><creator>Roilides, E.</creator><creator>Verweij, P. E.</creator><creator>Viscoli, C.</creator><creator>Ullmann, A. J.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201212</creationdate><title>ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS</title><author>Lortholary, O. ; Petrikkos, G. ; Akova, M. ; Arendrup, M. C. ; Arikan‐Akdagli, S. ; Bassetti, M. ; Bille, J. ; Calandra, T. ; Castagnola, E. ; Cornely, O. A. ; Cuenca‐Estrella, M. ; Donnelly, J. P. ; Garbino, J. ; Groll, A. H. ; Herbrecht, R. ; Hope, W. W. ; Jensen, H. E. ; Kullberg, B. J. ; Lass‐Flörl, C. ; Meersseman, W. ; Richardson, M. D. ; Roilides, E. ; Verweij, P. E. ; Viscoli, C. ; Ullmann, A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3842-b4ea42a0d6a0198eb440457e301eb1ddb0fb8102feeeff01bdf2e0242c0b7a603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antifungal Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Candida - drug effects</topic><topic>Candida - isolation & purification</topic><topic>Candidiasis</topic><topic>Candidiasis - complications</topic><topic>Candidiasis - diagnosis</topic><topic>Candidiasis - drug therapy</topic><topic>Candidiasis - prevention & control</topic><topic>Europe</topic><topic>Evidence-Based Medicine - standards</topic><topic>guideline</topic><topic>HIV AIDS</topic><topic>HIV Infections - complications</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lortholary, O.</creatorcontrib><creatorcontrib>Petrikkos, G.</creatorcontrib><creatorcontrib>Akova, M.</creatorcontrib><creatorcontrib>Arendrup, M. C.</creatorcontrib><creatorcontrib>Arikan‐Akdagli, S.</creatorcontrib><creatorcontrib>Bassetti, M.</creatorcontrib><creatorcontrib>Bille, J.</creatorcontrib><creatorcontrib>Calandra, T.</creatorcontrib><creatorcontrib>Castagnola, E.</creatorcontrib><creatorcontrib>Cornely, O. A.</creatorcontrib><creatorcontrib>Cuenca‐Estrella, M.</creatorcontrib><creatorcontrib>Donnelly, J. P.</creatorcontrib><creatorcontrib>Garbino, J.</creatorcontrib><creatorcontrib>Groll, A. H.</creatorcontrib><creatorcontrib>Herbrecht, R.</creatorcontrib><creatorcontrib>Hope, W. W.</creatorcontrib><creatorcontrib>Jensen, H. E.</creatorcontrib><creatorcontrib>Kullberg, B. J.</creatorcontrib><creatorcontrib>Lass‐Flörl, C.</creatorcontrib><creatorcontrib>Meersseman, W.</creatorcontrib><creatorcontrib>Richardson, M. D.</creatorcontrib><creatorcontrib>Roilides, E.</creatorcontrib><creatorcontrib>Verweij, P. E.</creatorcontrib><creatorcontrib>Viscoli, C.</creatorcontrib><creatorcontrib>Ullmann, A. J.</creatorcontrib><creatorcontrib>ESCMID Fungal Infection Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lortholary, O.</au><au>Petrikkos, G.</au><au>Akova, M.</au><au>Arendrup, M. C.</au><au>Arikan‐Akdagli, S.</au><au>Bassetti, M.</au><au>Bille, J.</au><au>Calandra, T.</au><au>Castagnola, E.</au><au>Cornely, O. A.</au><au>Cuenca‐Estrella, M.</au><au>Donnelly, J. P.</au><au>Garbino, J.</au><au>Groll, A. H.</au><au>Herbrecht, R.</au><au>Hope, W. W.</au><au>Jensen, H. E.</au><au>Kullberg, B. J.</au><au>Lass‐Flörl, C.</au><au>Meersseman, W.</au><au>Richardson, M. D.</au><au>Roilides, E.</au><au>Verweij, P. E.</au><au>Viscoli, C.</au><au>Ullmann, A. J.</au><aucorp>ESCMID Fungal Infection Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2012-12</date><risdate>2012</risdate><volume>18</volume><spage>68</spage><epage>77</epage><pages>68-77</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Clin Microbiol Infect 2012; 18 (Suppl. 7): 68–77
Mucosal candidiasis is frequent in immunocompromised HIV‐infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre‐HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole‐refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>23137138</pmid><doi>10.1111/1469-0691.12042</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2012-12, Vol.18, p.68-77 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273136347 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antifungal Agents - therapeutic use Antiretroviral Therapy, Highly Active Candida - drug effects Candida - isolation & purification Candidiasis Candidiasis - complications Candidiasis - diagnosis Candidiasis - drug therapy Candidiasis - prevention & control Europe Evidence-Based Medicine - standards guideline HIV AIDS HIV Infections - complications Humans Immunocompromised Host |
| title | ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T22%3A46%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ESCMID%20guideline%20for%20the%20diagnosis%20and%20management%20of%20Candida%20diseases%202012:%20patients%20with%20HIV%20infection%20or%20AIDS&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Lortholary,%20O.&rft.aucorp=ESCMID%20Fungal%20Infection%20Study%20Group&rft.date=2012-12&rft.volume=18&rft.spage=68&rft.epage=77&rft.pages=68-77&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1111/1469-0691.12042&rft_dat=%3Cproquest_cross%3E1273136347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273136347&rft_id=info:pmid/23137138&rfr_iscdi=true |